8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 1, 2012

FURIEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-34641	27-1197863
(Commission File Number)	(IRS Employer ID Number)

3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (919) 456-7800

__________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On November 1, 2012, Furiex Pharmaceuticals, Inc. issued a press release announcing its operating results for the quarter ended September 30, 2012. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits.

Exhibit No.	Description
99.1	Press release issued November 1, 2012, announcing operating results for the quarter ended September 30, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	FURIEX PHARMACEUTICALS, INC.
Date: November 1, 2012	/s/ Marshall H. Woodworth
	Marshall H. Woodworth Chief Financial Officer

EX-99

Exhibit 99.1

Contact

Media/Analysts/Investors:

Sailash Patel

919.456.7814

sailash.patel@furiex.com

Furiex Reports Third Quarter 2012 Financial Results

Third Quarter 2012 Highlights:

● Milestone revenue of $10.0 million related to Priligy® regulatory milestones.

● Royalty revenue of $5.6 million, an increase of $2.5 million (81.4%) from second quarter 2012.

● Amended Loan and Security Agreement providing $30.0 million in additional funding.

● Cash and short-term investments balance of $47.8 million as of September 30, 2012.

MORRISVILLE, N.C. (November 1, 2012) -Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2012.

Furiex recorded third quarter milestone revenue of $10.0 million. These regulatory milestones were related to achievement of new country marketing approvals for Priligy® and became due from the Menarini Group upon closing of the new license agreement on July 30, 2012.

Furiex recorded third quarter royalty revenue of $5.6 million, compared to $1.3 million for the same period in the prior year and $3.1 million in the second quarter of 2012. Royalty revenue included royalties related to Nesina® and Liovel® sales in Japan, and Priligy® sales in various countries outside of the United States.

Research and development expenses were $14.8 million for the quarter ended September 30, 2012, compared to $12.0 million for the same period in the prior year. The increase in research and development expenses from the prior year quarter ended September 30, 2011 was a result of the decision to progress with MuDelta Phase III clinical trials in early 2012 and the costs associated with its continued development, partially offset by decreases in spending for the discontinued PPD-10558 program and completion of the Phase II clinical trial work related to MuDelta and JNJ-Q2.

Third quarter selling, general and administrative expenses were $3.2 million for 2012, compared to $2.1 million for the third quarter of 2011. The increase in selling, general and administrative expenses were due primarily to increases in non-cash stock compensation expense of $0.4 million and increases in consulting expenses of $0.4 million.

Interest expense of $0.8 million for the third quarter of 2012 related entirely to our loan agreement with MidCap Funding III, LLC and Silicon Valley Bank.

Net loss was $3.3 million for the third quarter of 2012, compared to $13.0 million for the third quarter of 2011. The decrease in net loss of $9.7 million during the third quarter of 2012, as compared to the third quarter of 2011, relates to the changes in revenue and expenses previously described.

Net loss per share for the third quarter of 2012 was $0.33, compared to $1.32 for the third quarter of 2011.

"The Furiex team continues to advance the MuDelta Phase III clinical trials," said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “We have recruited slightly more than 30% of our targeted patient enrollment needed to complete these pivotal studies.”

"We have made significant strides on multiple fronts,” added Fred Eshelman, Pharm.D., chairman of Furiex. “MuDelta development remains on track, Nesina and Liovel royalty revenue from Japan continues to ramp up, Takeda has resubmitted New Drug Applications for alogliptin and alogliptin/pioglitazone to the FDA, restructuring of the Priligy agreements is complete and immediately accretive, and we have secured $30 million in additional funding to support operations. We believe we have laid a sound foundation for the development of our product portfolio.”

Furiex will conduct a live conference call and webcast Friday, November 2, 2012, at 9:00 a.m. ET to discuss its third quarter 2012 results and financial outlook for 2012 as well as provide an overview of its business and pipeline. A Q&A session will follow. All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at www.furiex.com. The webcast will be archived shortly after the call for on-demand replay. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in:	+1.877.677.9122 (U.S./Canada)
	+1.708.290.1401 (International)
Conference ID:	35741137

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, and three products on the market. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although Furiex attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause actual results to differ materially include the following: continuing losses and our potential need for additional financing; the risk of finding collaborators for our late-stage product candidates; progress of product candidates in clinical trials and regulatory approvals as it relates to receiving future milestone payments; inability of our existing collaborators to effectively market approved products for which we receive royalty and sales-based milestone payments; the risks and expense of continuing the research and development activities of our existing candidates; changes in the safety and efficacy profile of our existing candidates as they progress through research and development; potential U.S. Food and Drug Administration changes to its regulatory guidance; new collaborative agreements that we might enter into in the future; the costs of defending or prosecuting any patent opposition or litigation necessary to protect our proprietary technologies; and the other risk factors set forth from time to time in the SEC filings for Furiex, copies of which can be found on our website.

FURIEX PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2011			2012			2011			2012
Revenue:
Milestones	$	—		$	10,000		$	—		$	20,000
Royalties		1,272			5,577			2,505			11,297
Total revenue		1,272			15,577			2,505			31,297
Research and development expenses		12,024			14,798			38,123			54,919
Selling, general and administrative expenses		2,100			3,209			6,424			8,732
Depreciation and amortization		19			22			64			64
Total operating expenses		14,143			18,029			44,611			63,715
Operating loss		(12,871	)		(2,452	)		(42,106	)		(32,418	)
Interest expense		136			837			136			1,386
Other income, net		—			—			—			—
Loss before provision for income taxes		(13,007	)		(3,289	)		(42,242	)		(33,804	)
Provision for income taxes		6			(3	)		18			9
Net loss	$	(13,013	)	$	(3,286	)	$	(42,260	)	$	(33,813	)
Net loss per basic and diluted share	$	(1.32	)	$	(0.33	)	$	(4.28	)	$	(3.39	)
Weighted-average shares used to compute net loss per basic and diluted share:		9,881			10,015			9,881			9,974

FURIEX PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share data)
	December 31,			September 30,
	2011			2012
Assets
Current assets:
Cash and cash equivalents	$	33,628		$	40,342
Short-term investments		10,000			7,500
Accounts receivable, net		1,985			7,519
Prepaid expenses		214			589
Total current assets		45,827			55,950
Property and equipment, net		181			141
Goodwill		49,116			49,116
Other assets		—			275
Total assets	$	95,124		$	105,482
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$	147		$	7,577
Accrued expenses		10,422			12,354
Current portion of long-term debt		1,351			2,162
Total current liabilities		11,920			22,093
Long-term debt, net		8,649			37,838
Other long-term liabilities		232			256
Total liabilities		20,801			60,187
Common stock, $0.001 par value, 40,000,000 shares authorized; 9,949,422 and 10,015,297 shares issued and outstanding		10			10
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued or outstanding		—			—
Paid-in capital		158,438			163,223
Accumulated deficit		(84,125	)		(117,938	)
Total shareholders’ equity		74,323			45,295
Total liabilities and shareholders’ equity	$	95,124		$	105,482